WO/2014/102778 AGENTS FOR TREATING GENETIC DISEASES RESULTING FROM NONSENSE MUTATIONS, AND METHODS FOR IDENTIFYING THE SAME||WO||03.07.2014|
||PCT/IL2013/051058||RAMOT AT TEL-AVIV UNIVERSITY LTD.||ROSIN-ARBESFELD, Rina|
Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.
WO/2014/091368 IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS||WO||19.06.2014|
||PCT/IB2013/060631||PFIZER LIMITED||OMOTO, Kiyoyuki|
Chemical Compounds The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5- c]pyridazine derivatives of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R 2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
WO/2014/081343 PHARMACEUTICAL COMPOSITION CONTAINING NALBUPHINE HYDROCHLORIDE, USE THEREOF TO TREAT MODERATE TO SEVERE PAIN AND METHOD FOR PRODUCING SAID PHARMACEUTICAL COMPOSITION||WO||30.05.2014|
||PCT/RU2013/001031||OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "NPK TRIFARMA"||LYAPUNOV, Nikolay Alexandrovich|
The invention relates to the field of medicine and the pharmaceutical chemical industry. A pharmaceutical composition in suppository form for treating moderate to severe pain comprises the active principle nalbuphine hydrochloride and a suppository base. As the suppository base, the composition contains a hydrophilic emulsion base that includes binders, a poloxamer, a filler, an emulsifier, and propylene glycol and polyethylene oxide-400 as a solvent. The binders contained in the composition are preferably polyethylene oxide 4000 and polyethylene oxide 1500, and the poloxamer is poloxamer 188. The filler contained in the composition is preferably solid fat. Further, the emulsifier contained in the composition is preferably a complex emulsifier in the form of a blend of a type 1 emulsifier and a type 2 emulsifier. Proposed is a method for producing a pharmaceutical composition, according to which nalbuphine hydrochloride is dissolved in propylene glycol, the solution is mixed with a melted suppository base and homogenized; the liquid suppository mass is dosed into blister pockets and cooled.
WO/2014/072570 DISC TUMBLER CYLINDER LOCK AND KEY COMBINATION||WO||15.05.2014|
||PCT/FI2013/050733||ABLOY OY||MALINEN, Perttu|
The rotation limiter disc means (10) of a disc tumbler cylinder lock-key-combination are arranged to be rotated by a key (11), wherein the rotation limiting means have no pieces non-rotatably attached to the inner cylinder (1). The rotation limiter disc means (10) are composed of a frame piece (10B) and a limiter piece (10A). The frame piece (10B) is a circular disc having an opening (53) in the middle of the disc. The opening extends up to the border (52) of the disc widening towards the border, and to the section on the wider side of the opening is disposed a limiter piece (10A). On the inner surface (62) of the inner cylinder (1) is a recess (25) at the site of the limiter disc means (10). The key (11) has at least one bevel-edged cavity (12).
WO/2014/066485 STABLE PRESERVATIVE-FREE MYDRIATIC AND ANTI-INFLAMMATORY SOLUTIONS FOR INJECTION||WO||01.05.2014|
||PCT/US2013/066349||OMEROS CORPORATION||DEMOPULOS, Gregory, A.|
The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
WO/2014/058747 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS||WO||17.04.2014|
||PCT/US2013/063612||MERCK SHARP & DOHME CORP.||ARRINGTON, Kenneth, L.|
Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
WO/2014/058801 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION||WO||17.04.2014|
||PCT/US2013/063731||IDENIX PHARMACEUTICALS, INC.||GOSSELIN, Gilles|
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: (2001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.
WO/2014/053491 INHIBITORS OF HISTONE DEMETHYLASES||WO||10.04.2014|
||PCT/EP2013/070457||EPITHERAPEUTICS APS||LABELLE, Marc|
The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form (I).
WO/2014/053891 METHOD FOR THE DETOXIFICATION OF GLUTEN PROTEINS FROM GRAINS OF CEREALS||WO||10.04.2014|
||PCT/IB2013/000797||UNIVERSITA' DEGLI STUDI DI FOGGIA||DI LUCCIA, Aldo|
The method allows to obtain gluten detoxified flours suitable for the preparation of bakery products and pasta made from wheat. With the use of the method gluten proteins undergo structural changes that do not activate in patients suffering from celiac disease, the cascade of inflammatory cytokines. Such structural changes, in addition, do not affect the technical properties of the flours that form the dough, therefore allowing the preparation of detoxified products, similar in taste and appearance to those commonly used in Mediterranean diet and which are intended not only for the people who suffer from intolerance to gluten, but for the whole population. The widespread use of such detoxified products in large part of the population has the purpose, in a totally innovative way, to provoke the reduction of gluten's effects in people's health and therefore to the decrease in the incidence of celiac disease.
WO/2014/045156 NOVEL BICYCLIC PYRIDINONES||WO||27.03.2014|
||PCT/IB2013/058347||PFIZER INC.||AM ENDE, Christopher William|
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.